US009044439B2

(12) **United States Patent**
Garner et al.

(10) **Patent No.: US 9,044,439 B2**
(45) **Date of Patent: *Jun. 2, 2015**

(54) **LOW DOSE LIPOIC AND PHARMACEUTICAL COMPOSITIONS AND METHODS**

(75) Inventors: **William Garner**, Eastport, ME (US); **Margaret Garner**, Eastport, ME (US)

(73) Assignee: **Encore Health, LLC**, Roanoke, VA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 353 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/267,208**

(22) Filed: **Nov. 7, 2008**

(65) **Prior Publication Data**

US 2009/0227677 A1 Sep. 10, 2009

Related U.S. Application Data

(60) Provisional application No. 61/033,870, filed on Mar. 5, 2008, provisional application No. 61/060,487, filed on Jun. 11, 2008, provisional application No. 61/077,186, filed on Jul. 1, 2008.

(51) **Int. Cl.**
A61K 31/35 (2006.01)
A61K 31/19 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/19*** (2013.01)

(58) **Field of Classification Search**
USPC 514/439, 440
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,238,224	A	3/1966	Ohara et al.
3,855,240	A	12/1974	Mueller
4,210,667	A	7/1980	Sarges et al.
4,755,528	A	7/1988	DuPriest et al.
5,395,356	A	3/1995	King et al.
5,459,133	A	10/1995	Neufeld
5,465,737	A	11/1995	Schachar
5,466,680	A	11/1995	Rudy
5,476,515	A	12/1995	Kelman et al.
5,488,050	A	1/1996	Neufeld
5,503,165	A	4/1996	Schachar
5,527,774	A	6/1996	Girard
5,529,076	A	6/1996	Schachar
5,624,955	A	4/1997	Nagasawa et al.
5,665,770	A	9/1997	Terao et al.
5,686,450	A	11/1997	Hellberg et al.
5,688,828	A	11/1997	Hellberg et al.
5,691,379	A	11/1997	Ulrich et al.
5,722,952	A	3/1998	Schachar
5,817,630	A	10/1998	Hofmann et al.
5,843,184	A	12/1998	Cionni
5,869,468	A	2/1999	Freeman
5,874,455	A	2/1999	Terao et al.
5,888,243	A	3/1999	Silverstrini
6,007,510	A	12/1999	Nigam
6,013,462	A	1/2000	Kauvar et al.
6,030,950	A	2/2000	Ohlenschlager
6,063,116	A	5/2000	Kelleher
6,214,044	B1	4/2001	Silverstrini
6,288,106	B1	9/2001	Pearson et al.
6,313,164	B1	11/2001	Fujita et al.
6,339,102	B1	1/2002	Meyerhoff et al.
6,387,945	B2	5/2002	Packer et al.
6,472,541	B2	10/2002	Tsien et al.
6,664,287	B2	12/2003	Avery et al.
6,703,039	B2	3/2004	Xia et al.
6,743,779	B1	6/2004	Unger et al.
6,923,955	B2	8/2005	Till et al.
7,164,943	B2	1/2007	Roy
7,914,815	B2	3/2011	Till et al.
7,935,332	B2	5/2011	Till
8,147,816	B2	4/2012	Till et al.
8,410,162	B2	4/2013	Garner et al.
8,647,612	B2	2/2014	Garner et al.
8,697,109	B2	4/2014	Garner et al.
2002/0025311	A1	2/2002	Till
2002/0035243	A1	3/2002	Imfeld et al.
2003/0187058	A1	10/2003	Hasselwander et al.
2003/0228299	A1	12/2003	Droy-Lefaix et al.
2004/0044227	A1	3/2004	Klatt et al.
2004/0092586	A1	5/2004	Ogata et al.
2005/0101677	A1	5/2005	Till
2005/0112113	A1	5/2005	Till et al.
2005/0130881	A1	6/2005	Shashoua
2005/0137124	A1	6/2005	Castillejos

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 369 880	5/1990
WO	WO 93/25166	12/1993

(Continued)

OTHER PUBLICATIONS

Ip C, Ganther HE. 1992. Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis. 13(7): 1167-70.
U.S. Appl. No. 12/815,586, filed Jun. 15, 2010, Garner et al.
U.S. Appl. No. 12/815,526, filed Jun. 15, 2010, Garner et al.
Bustamante, J., et al., 1998. α-Lipoic Acid in Liver Metabolism and Disease. *Free Radical Biology & Medicine* 24: No. 6 1023-1039.
Cagini, C. MD, et al. 2010. Study of alpha-lipoic acid penetration in the human aqueous humour after topical administration. Clinical and Experimental Ophthalmology "Accepted Article" doi: 10.1111/j.1442-9071.2010.02319.x.
Giblin FJ, et al. 1979. The effects of X-irradiation on lens reducing systems. Investigative Ophthalmology & Visual Science 18:468-475.
Kramár P, et al. 1987. Thermal cataract formation in rabbits. NCBI Pubmed abstract, PMID: 3426637, abstract of Bioelectromagnetics 8:397-406.

(Continued)

Primary Examiner — Zohreh Fay
(74) *Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox PLLC

(57) **ABSTRACT**

Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, and lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases.

6 Claims, 5 Drawing Sheets